Biotech Enterprise Sangui Starts Expanding Internationally Recording Large Order From Mexico

Dec 21, 2012, 08:00 ET from Sangui Bio Tech International Inc.

WITTEN, Germany, December 21, 2012 /PRNewswire/ --

Effective now, Sangui BioTech International, Inc. (Symbol: SGBI ) has its wound therapeutic Granulox being sold in Mexico. Sangui BioTech GmbH has licensed the respective rights to its affiliate SastoMed GmbH. SastoMed is already distributing Granulox in Germany. At the outset of the international expansion a large order could be recorded yielding an expected sales volume of over EUR500,000.

The largest customer purchasing from the first delivery of Granulox to Mexico is the State of Tamaulipas. Here, governmental health institutions will be equipped with the wound therapeutic. Granulox is being applied as a spray. Main indications are chronic wounds, originating in most cases in lack of oxygen supply (hypoxia) or insufficient blood flow to the respective part of the body. In many cases diabetes is the primary disease. Diabetes affects the blood vessels thus causing circulation disturbances in legs and feet. Around 37 million treatments per annum occur on a global scale. More than one fourth of those are being registered in Latin America. Expansion to Mexico is seen as the first step to addressing this market.

The expansion shall be promoted based on a contractually agreed cooperation with the Mexico based distribution partner Bio-Mac Pharma the management of which has a track record of successfully supporting the sales of other renowned pharmaceutical companies like Pfizer, Novartis and Schering Plough.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB marketplace ( SGBI) and the OTC market of Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing
Phone: +49(179)-7963472
Fax: +49(2302)-915191

SOURCE Sangui Bio Tech International Inc.